In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Left atrial global longitudinal strain as a new predictor of cardiotoxicity in breast cancer patients

Session Cardiovascular events in malignancies: from prediction to prevention

Speaker Assistant Professor Hyukjin Park

Congress : ESC Congress 2018

  • Topic : cardiovascular disease in special populations
  • Sub-topic : Cardio-Oncology
  • Session type : Rapid Fire Abstracts
  • FP Number : 6135

Authors : H Park (Gwangju,KR), M Kim (Gwangju,KR), HK Jeong (Gwangju,KR), KH Kim (Gwangju,KR), HY Kim (Gwangju,KR), JY Cho (Gwangju,KR), HJ Yoon (Gwangju,KR), Y Ahn (Gwangju,KR), MH Jeong (Gwangju,KR), JG Cho (Gwangju,KR), JC Park (Gwangju,KR)

H. Park1 , M. Kim2 , H.K. Jeong1 , K.H. Kim1 , H.Y. Kim1 , J.Y. Cho1 , H.J. Yoon1 , Y. Ahn1 , M.H. Jeong1 , J.G. Cho1 , J.C. Park1 , 1Chonnam National University Hospital, Cardiology - Gwangju - Korea Republic of , 2Chonnam National University Hospital, Nephrology - Gwangju - Korea Republic of ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 1272

Background/Introduction: As the numbers of cancer survival increase, early detection and treatment of chemotherapy induced cardiotoxicity become more important.

Purpose: The authors investigated whether the structural and functional changes of the left atrium (LA) can be used as a predictor of future chemotherapy induced left ventricular dysfunction (LVD).

Methods: A total of 72 female breast cancer patients without chemotherapy-induced LVD on echocardiography at baseline and 6 months of follow up were included for this analysis. Echocardiography examinations were serially performed at baseline before the initiation of chemotherapy, at 6, 12, and 18 months of clinical follow up. Chemotherapy-induced LVD was defined as the development of LV ejection fraction (EF) <55% and the decrease in LVEF >10% from the baseline LVEF on follow up echocardiography at 12 or 18 months in the present study. Besides conventional echocardiographic measurements, global longitudinal strain (GLS) of the LA and the left ventricle (LV) were checked and compared.

Results: Chemotherapy induced LVD was developed 13 patients (18.1%), and LVEF was decreased (64.1±6.0 to 61.4±8.9%, p=0.001) over the follow up period. LA GLS gradually decreased (-25.4±1.4 to -21.1±2.4%, p<0.001) over the follow up period, and the decrease of LA GLS was more prominent in patients with chemotherapy-induced LVD than in patients without LVD (-25.8±1.3 to -17.8±1.9% vs -25.3±1.4 to -21.8±1.8%, p<0.001). LA end-systolic volume (50.2±5.7 to 51.5±6.4%, p<0.001) and E/E' (7.9±1.2 to 8.1±1.7%, p=0.047) were also increased during the 6-month follow up. LA GLS on follow echocardiography at 6 months were significantly lower in patients with chemotherapy induced LVD group than in patients without LVD (-21.9±1.3 vs -23.8±1.6, p<0.001). By receiver operation characteristic curve analysis, the optimal cutoff value for predicting upcoming chemotherapy induced LVD was LA GLS > -22.5% on 6-month follow up echocardiography (76.9% sensitivity and 71.2% specificity, AUC 0.829).

Conclusions: The present study demonstrated that structural and functional changes of the LA as measured by LA GLS precedes before developing overt chemotherapy induced LVD. Therefore, the serial measurement of LA GLS can be used as a useful parameter in the prediction of future chemotherapy induced cardiotoxicity.

Temporal changes in LA strain

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are